Protagonist Gross Profit from 2010 to 2024

PTGX Stock

USD 44.95 0.12 0.27%

Protagonist Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Protagonist Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2014-12-31

Previous Quarter

3.3 M

Current Value

4.7 M

Quarterly Volatility

40.8 M

Yuan Drop

Covid

Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.

Check out the analysis of Protagonist Therapeutics Correlation against competitors.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Latest Protagonist Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Protagonist Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Protagonist Therapeutics minus its cost of goods sold. It is profit before Protagonist Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Protagonist Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 26.58 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Protagonist Gross Profit Regression Statistics

	Arithmetic Mean	16,896,400
	Geometric Mean	0.00
	Coefficient Of Variation	130.21
	Mean Deviation	18,067,227
	Median	231,000
	Standard Deviation	22,000,253
	Sample Variance	484T
	Range	63.3M
	R-Value	0.84
	Mean Square Error	157.7T
	R-Squared	0.70
	Significance	0.0001
	Slope	4,108,268
	Total Sum of Squares	6776.2T

Protagonist Gross Profit History

	2024	63 M
	2023	60 M
	2022	26.6 M
	2021	24.6 M
	2020	28.6 M
	2019	231 K
	2018	30.9 M

Other Fundumenentals of Protagonist Therapeutics

Gross Profit Margin

Protagonist Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Long Term Debt Total	Capital Surpluse	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Short Term Debt
Total Assets		-0.25	0.99	-0.87	-0.85	0.39	0.5	0.96	0.3	-0.8	1.0	0.1	0.51	0.78	0.84	0.91	-0.77	0.87	0.9	0.75
Total Stockholder Equity	-0.25		-0.35	-0.09	0.0	-0.57	0.53	-0.32	-0.59	0.22	-0.24	-0.01	-0.34	-0.11	-0.33	-0.05	0.06	-0.01	-0.03	-0.46
Net Tangible Assets	0.99	-0.35		-0.84	-0.81	0.44	0.39	0.96	0.34	-0.77	0.98	0.03	0.46	0.74	0.84	0.88	-0.78	0.85	0.88	0.79
Net Debt	-0.87	-0.09	-0.84		0.91	-0.26	-0.66	-0.74	-0.28	0.71	-0.87	-0.19	-0.23	-0.73	-0.69	-0.93	0.88	-0.82	-0.83	-0.68
Retained Earnings	-0.85	0.0	-0.81	0.91		-0.25	-0.64	-0.8	-0.45	0.84	-0.86	-0.17	-0.43	-0.85	-0.65	-0.99	0.86	-0.82	-0.86	-0.81
Accounts Payable	0.39	-0.57	0.44	-0.26	-0.25		0.17	0.37	0.42	-0.62	0.39	0.08	0.23	0.54	0.6	0.29	-0.37	0.06	0.11	0.29
Net Receivables	0.5	0.53	0.39	-0.66	-0.64	0.17		0.42	-0.19	-0.62	0.5	0.07	0.34	0.65	0.52	0.63	-0.45	0.38	0.44	0.1
Short Term Investments	0.96	-0.32	0.96	-0.74	-0.8	0.37	0.42		0.24	-0.8	0.96	0.05	0.62	0.78	0.78	0.86	-0.69	0.85	0.89	0.76
Total Liab	0.3	-0.59	0.34	-0.28	-0.45	0.42	-0.19	0.24		-0.37	0.29	0.09	0.06	0.31	0.3	0.4	-0.4	0.19	0.2	0.67
Long Term Investments	-0.8	0.22	-0.77	0.71	0.84	-0.62	-0.62	-0.8	-0.37		-0.8	-0.24	-0.62	-0.98	-0.69	-0.84	0.76	-0.63	-0.7	-0.69
Total Current Assets	1.0	-0.24	0.98	-0.87	-0.86	0.39	0.5	0.96	0.29	-0.8		0.12	0.5	0.79	0.83	0.91	-0.78	0.88	0.91	0.75
Common Stock	0.1	-0.01	0.03	-0.19	-0.17	0.08	0.07	0.05	0.09	-0.24	0.12		0.15	0.35	-0.22	0.13	-0.19	0.17	0.18	0.18
Property Plant Equipment	0.51	-0.34	0.46	-0.23	-0.43	0.23	0.34	0.62	0.06	-0.62	0.5	0.15		0.57	0.47	0.44	-0.16	0.28	0.36	0.41
Long Term Debt	0.78	-0.11	0.74	-0.73	-0.85	0.54	0.65	0.78	0.31	-0.98	0.79	0.35	0.57		0.6	0.85	-0.78	0.68	0.74	0.67
Long Term Debt Total	0.84	-0.33	0.84	-0.69	-0.65	0.6	0.52	0.78	0.3	-0.69	0.83	-0.22	0.47	0.6		0.7	-0.53	0.51	0.56	0.48
Capital Surpluse	0.91	-0.05	0.88	-0.93	-0.99	0.29	0.63	0.86	0.4	-0.84	0.91	0.13	0.44	0.85	0.7		-0.88	0.85	0.88	0.82
Current Deferred Revenue	-0.77	0.06	-0.78	0.88	0.86	-0.37	-0.45	-0.69	-0.4	0.76	-0.78	-0.19	-0.16	-0.78	-0.53	-0.88		-0.82	-0.82	-0.8
Net Invested Capital	0.87	-0.01	0.85	-0.82	-0.82	0.06	0.38	0.85	0.19	-0.63	0.88	0.17	0.28	0.68	0.51	0.85	-0.82		0.99	0.75
Net Working Capital	0.9	-0.03	0.88	-0.83	-0.86	0.11	0.44	0.89	0.2	-0.7	0.91	0.18	0.36	0.74	0.56	0.88	-0.82	0.99		0.76
Short Term Debt	0.75	-0.46	0.79	-0.68	-0.81	0.29	0.1	0.76	0.67	-0.69	0.75	0.18	0.41	0.67	0.48	0.82	-0.8	0.75	0.76

Click cells to compare fundamentals

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	60 M	63 M
Gross Profit Margin	0.87	0.74

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC